No checkpoint glory for Acrivon
Prexasertib data worsen again, and biomarkers are up in the air.
ASCO-GI – Astellas makes a case for its Vyloy triplet
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
ASCO-GI – Astellas focuses on a degrader-chemo combo
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
Different dosing enlivens Enliven’s share price
ELVN-001 is made to look more like Terns’ TERN-701.
BridgeBio Oncology shows early promise
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
Incyte does TGF-beta differently
Four months after yielding first-in-human data INCA33890 enters phase 3.
ASCO-GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
Christmas oncology roundup
The holiday period included Genmab’s discontinuation of acasunlimab.
